🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Amazing presentation by Robert Weinkove at #ASH2023 as he leads a group developing a 3rd generation CART product for patients in New Zealand 🇳🇿 addressing a major unmet need where no CART access exists. Very promising efficacy and safety signals to date! 👏

Our lab is hiring! Looking for a mixed dry-wet lab or computational postdoc to investigate biomarkers of treatment response and resistance in B-cell #lymphomas using bulk and single cell multiomics. Please RT. Reach out if interested in the role jobs.ac.uk/job/DGB780/pos…

We’re hiring! Research Fellows 2025 at Monash Health: - Lymphoma / Cellular Therapies - Myeloid Diseases Come work with our fantastic team! Chyn C Jake Shortt Erica Wood Stephen Opat and many more Monash University School of Clinical Sciences careers.monashhealth.org/job/Clayton-20…

We (Monash Haematology team) are running for Monash Haematology and will appreicate any support no matter how big or small! Proceeds will go to improving patient care and wellbeing 🫰🏻🫰🏻🫰🏻🙏🏻🙏🏻 runmelbourne24.grassrootz.com/monashhealth/m…

With great support from ⁦Haematology Peter MacCallum CC & Royal Melbourne⁩ and the cell therapies platform ⁦Hudson Institute of Medical Research⁩ our cell therapies and autograft program ⁦Monash Health⁩ is kicking goals and looking for a Quality Officer. Please share careers.monashhealth.org/job/Clayton-Ce…

At our weekly clinical virtual round today it was notable that this month (for the first time ever!) all inpatient Haematology units at Monash Health are being led by early/mid career female academic haematologists 👏 👏👏 So proud of our team!

ALLG’s CML13 ASCEND trial has been pre-published in Blood. Led by A/Prof David Yeung, CML13 was one of the first trials globally to use asciminib in newly diagnosed CML patients. Read the pre-publication: tinyurl.com/2kjtym8y.

Take your next step towards becoming a clinical researcher in #hematology with #EHA Clinical Research Training in Hematology (#CRTH). Apply by August 30 to join this comprehensive program, spanning topics from trial design to grant writing. Apply now: eha.fyi/CRTH25

Really excited to share our review article on updates in the biology, prognostication and treatment of nodular lymphocyte predominant Hodgkin lymphoma. A massive thanks to Chan Cheah and Graham Collins for your guidance and support. doi.org/10.3324/haemat…

Great to be at #Blood2024 in Brisbane! Amazing program from ⁦⁦Dr Andrea Henden⁩ ⁦Dr Anastazia Keegan⁩ and the organising committees!

#Blood2024 Opening Session fantastic presentation on gene therapy for Sickle Cell Disease by our international expert Dr Anthea Greenway of RCH and ⁦Monash Health⁩ 👏

Fantastic presentation by (2nd year registrar!) Dr Samantha Kurniawan showing NSW leadership to harmonise TI-MM protocols within the myeloma abstracts session at #Blood2024 and great chairing by Nicholas Weber and Georgia McCaughan 👏🩸

Two (2!) fantastic IIT abstracts in the HSANZ Presidential Symposium from @DrElizaHawkes (RaDD) and Allison Barraclough (WAMM) from their ONJ Cancer Research Institute group at #Blood2024 Women in Lymphoma - [email protected] Australasian Leukaemia & Lymphoma Group (ALLG) 👏 🩸

Prof. Paula Marlton delivering the Carl de Gruchy Oration at #Blood2024 🥇 🩸 👏

Delighted to share the practice-changing #STARGLO study manuscript at The Lancet today. Transplant-ineligible DLBCL should no longer be considered a palliative scenario #lymsm Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-G... sciencedirect.com/science/articl…

🔬 Discover the latest on emerging therapies for DLBCL at first relapse! 📚 Understand key factors for CAR T-cell eligibility and refine your skills in personalized treatment selection. 📊 Learn more: ms.spr.ly/6016oD7vE 💥 Featuring: Gareth Gregory Natacha Bolaños #ASH24

Reflecting on my first ASH 11 years ago and seeing experts present in Satellite Symposia, didn’t imagine I’d ever be on the stage. Many thanks to Medscape and co-panellists for a great session - was a lot of fun! #ASH2024 🙏

CONGRESS | #EHA2025 | POSTER Gareth P. Gregory Gareth Gregory Monash University shares updated efficacy and safety of Glofit-GemOx vs R-GemOx in pts with R/R DLBCL after ≥1 LOT after 2-year follow up of the phase III STARGLO trial. Glofit-GemOx continued to confer a superior OS,